Research Centre: The University of Adelaide
Location: 4 North Terrace, Adelaide SA 5000, Australia
Lead Researcher: Professor Chris Rayner
HREC: This study has been reviewed and approved by the CALHN Human Research Ethics Committee

Around 462 million people worldwide have been diagnosed and are living with type 2 diabetes. With so many people having to deal with this illness, it’s no wonder researchers have been working tirelessly to try and improve the lives of those with type 2 diabetes. That’s where researchers from the University of Adelaide come in.

Researchers are focusing on the crucial role that hormones released from the intestines have in regulating blood glucose levels after meals, particularly a hormone called Glucose-dependent Insulinotropic Polypeptide (GIP). This study aims to deepen our understanding of GIP’s function in managing blood glucose levels and how a novel tool might be able to block its actions and see the effects it has on blood glucose regulation. Dive into a revolutionary adventure at the University of Adelaide, where they’re not just studying diabetes — they’re redefining its future. Join now!

• Participants will be given an honorarium of up to $520 for participating in this study.
• Participants may experience improvements in their blood glucose regulation.
• Participants will be contributing valuable information that may benefit those with type 2 diabetes in the future.
• Participants will be helping to advance medical research.

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
• Any information that you provide will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

• Individuals aged 40-79 years who are diagnosed with type 2 diabetes
• Must be managing diabetes through lifestyle changes or by taking metformin only
• Must have an average blood sugar (glucose) level of 7.0 – 8.1 mmol/mol
• Must have a BMI of 20 – 35 kg/m²
• Must not be using any medication that may affect gastrointestinal function, body weight, or appetite
• Must not have a substance or alcohol use disorder
• Must not smoke more than 10 cigarettes a day
• Must not be a vegetarian
• Must be able to attend 4 study visits at the research site over approximately 12 weeks

The study team will explain the research in its entirety but some details are:

• Participants must be available from 8:00 to 14:00 for two visits in the first week and two visits in the twelfth week after an overnight fast.
• Participants will be required to take part in necessary assessments and medical tests, including blood tests to ensure their blood count, iron levels, kidney, and liver functions are normal.
• Participants will be assigned to a treatment of an oral antidiabetic drug, sitagliptin, once daily for 12 weeks.
• Participants will be given a ‘takehome’ meal for each study visit, which is to be eaten on the evening prior to the visit. Participants may drink water with the meal and will be required to fast overnight with no water after 22:00.

The University of Adelaide
By every measure, the University of Adelaide—a member of Australia’s prestigious Group of Eight research-intensive universities—stands tall among the world’s leading institutions of learning and innovation. The clearest indication of this is our consistently high rating by the most respected international assessment bodies: QS World University Rankings, Times Higher Education, and Shanghai Jiao Tong’s Academic Rankings of World Universities (ARWU). All consider us one of the top 1% of Universities worldwide, and the top university in our state. We’re equally proud of the fact that the vast majority of our research is rated ‘above or well above world standard’ by the Australian Research Council’s Excellence in Research Australia program.

Please note:
Due to the COVID-19 pandemic, the researchers would like to assure the participants that ensuring their and the study staff’s safety is of utmost importance.